Understanding the Selectivity of Casodex, a New Antiandrogen
Author Information
Author(s): S.N. Freeman, W.I.P. Mainwaring, B.J.A. Furr
Primary Institution: The University of Leeds; ICI Pharmaceuticals
Hypothesis
What explains the peripheral selectivity of Casodex compared to other antiandrogens?
Conclusion
Casodex does not increase serum LH and testosterone levels in intact male rats, suggesting it has a peripheral selectivity due to its inability to penetrate the blood-brain barrier.
Supporting Evidence
- Casodex showed a relative binding affinity of 0.267 for the androgen receptor.
- Daily treatment with Casodex did not change serum LH and testosterone levels in rats.
- Flutamide treatment resulted in significantly increased serum LH and testosterone levels.
Takeaway
Casodex is a new medicine that helps treat prostate cancer without causing certain side effects that other similar medicines do, because it doesn't affect the brain.
Methodology
The study involved administering Casodex and flutamide to male Wistar rats and measuring serum LH and testosterone levels, as well as conducting androgen receptor binding assays.
Limitations
The study was conducted only in male rats, and the results may not directly translate to humans.
Participant Demographics
Specific pathogen-free albino male Wistar rats
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website